Supernus flies high on FDA OK for Trokendi XR in epilepsy
This article was originally published in Scrip
Investors rallied around shares of Supernus Pharmaceuticals in a big way on 19 August, with the company's stock soaring as high as 26.5% after the US FDA granted its approval for the Rockville, Maryland specialty pharma to market its once-daily extended release formulation of topiramate under the brand-name Trokendi XR as a treatment for patients with epilepsy.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.